Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)

American Heart Journal

Volumn 150, Issue 1, 2005, Pages 123-131

  Konstam, Marvin A ^a   Neaton, James D ^b   Poole Wilson, Philip A ^c   Pitt, Bertram ^d   Segal, Robert ^e   Sharma, Divakar ^e   Dasbach, Erik J ^e   Carides, George W ^e   Dickstein, Kenneth ^f   Riegger, Günter ^g   Camm, A John ^h   Martinez, Felipe A ⁱ   Bradstreet, Deborah C ^e   Ikeda, Leila S ^e   Santoro, Emanuela P ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f UNIVERSITY OF BERGEN   (Norway)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SAMPLE SIZE; SURVIVAL RATE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; MALE; SURVIVAL;

EID: 23244454727     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.10.035     Document Type: Article

References (14)

1. J.F. Williams, M.R. Bristow, and M.B. Fowler Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Evaluation and Management of Heart Failure) Circulation 92 1995 2764 2784
2. Task Force of the Working Group on Heart Failure of the European Society of Cardiology Guidelines: the treatment of heart failure Eur Heart J 18 1997 736 753
3. J.N. Cohn The management of chronic heart failure N Engl J Med 335 1996 490 498
4. B. Pitt, R. Segal, and F.A. Martinez Randomised trial of losartan versus captopril in patients over 65 with heart failure Lancet 349 1997 747 752
5. B. Pitt, P.A. Poole-Wilson, and R. Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the losartan heart failure survival study ELITE II Lancet 355 2000 1582 1587
6. C.B. Granger, J.J.V. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial Lancet 2003 [Published online September 1]
7. J.N. Cohn, G. Tognoni the Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
8. J.J.V. McMurray, J. Östergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-added trial Lancet 2003 [Published online September 1]
9. B. Pitt, P. Poole-Wilson, R. Segal On behalf of the ELITE II Study Investigators Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the losartan heart failure survival study ELITE II J Card Fail 5 1999 146 154
10. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72
11. J. Cook, H. Glick, and B. Kinosian An assessment of the "ladder of life" score as a value measure for health status in congestive heart failure Med Decis Making 13 1993 386
12. M. Gail, and R. Simon Testing for qualitative interactions between treatment effects and patient subsets Biometrics 41 1985 361 372
13. K. Dickstein, J. Kjekshus the OPTIMAAL Steering Committee for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Lancet 360 2002 752 760
14. M.A. Pfeffer, J.J.V. McMurray, and E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906